Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program - 2The Best 20 Photography Instagram Records to Follow
- 3NASA just launched Artemis 2. What happens today could make or break the moon mission
- 4Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- 5Federal judge upholds Hawaii's new climate change tax on cruise passengers
- Jubilant FoodWorks to scrap Dunkin’ franchise arrangement in India
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- What's A Decent FICO rating?
- Electric Vehicles for Eco-Accommodating Driving
- NASA unveils close-up pictures of the comet popping by from another star
- What to know as New York City nurses strike for a 3rd day
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- 19 Peculiar Films You Shouldn't Watch With Your Mum
